Programs & products

IPH45 is a novel and differentiated exatecan-Antibody Drug Conjugate targeting Nectin-4 In preclinical PDX models of urothelial tumors, IPH45 has stronger activity than approved Nectin-4 targeting EV...

Positive final results of lacutamab TELLOMAK Phase 2 trial in Sézary syndrome presented at ASH Annual Meeting 2023; final data in mycosis fungoides to be shared at an upcoming medical congress...

IPH45 abstract selected for oral presentation at AACR Annual Meeting 2024 Preclinical data support further development of IPH45, a differentiated topoisomerase I inhibitor ADC targeting Nectin-4...

Phase 1/2 study is evaluating IPH6501, a first-in-class CD20-targeting tetraspecific natural killer cell engager, from ANKET® platform, for the treatment of CD20-expressing B-cell Non-Hodgkin's...

FDA lifts partial clinical hold on lacutamab clinical program Fatal case related to disease progression and unrelated to the treatment Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ”...

Sanofi to exercise one option to license a new ANKET ® program from Innate; After a research collaboration period, Sanofi will be responsible for all development, manufacturing and commercialization...

SAR443579/IPH6101, ANKET ® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under...

Results confirm promising clinical activity, durable responses and favorable safety of lacutamab in heavily pretreated post-mogamulizumab Sézary Syndrome patients. Virtual KOL event will be held on...

The event will highlight positive results from the TELLOMAK Phase 2 Trial with lacutamab in heavily pretreated patients with relapsed and refractory Sézary syndrome which have been selected for oral...

Positive final results of lacutamab TELLOMAK Phase 2 trial in Sézary syndrome selected for oral presentation and preliminary data in Peripheral T Cell lymphoma to be displayed in a poster at ASH...